Lipid parameters for measuring risk of cardiovascular disease - PubMed (original) (raw)
Review
Lipid parameters for measuring risk of cardiovascular disease
Benoit J Arsenault et al. Nat Rev Cardiol. 2011 Apr.
Abstract
Besides measuring blood pressure and glucose levels, assessing the lipid spectrum is the method most commonly used to identify individuals at high risk of cardiovascular disease (CVD), as well as those who are likely to benefit most from lipid-lowering therapy. Although lowering LDL-cholesterol levels is the primary target of therapy in most clinical guidelines, accumulating evidence indicates that other lipoprotein-lipid measurements could provide a predictive value over and above that of LDL-cholesterol levels. For example, individuals treated with statins who achieve low LDL-cholesterol levels, but have high concentrations of either non-HDL cholesterol or apolipoprotein (apo) B, remain at increased cardiovascular risk. Similarly, individuals with low levels of either HDL cholesterol or apo A-I are also likely to experience cardiovascular events, despite having normal LDL-cholesterol levels. The residual cardiovascular risk, beyond that characterized by LDL-cholesterol levels alone, is exacerbated by physical inactivity and abdominal obesity, which are both increasingly prevalent risk factors for CVD. In this Review, we discuss the measurement of various lipoprotein-lipid parameters for the prediction of CVD risk, and their importance in identifying those patients who are likely to benefit from lipid-lowering therapy. The impact of recent studies on clinical guidelines is also considered.
© 2011 Macmillan Publishers Limited. All rights reserved
Similar articles
- Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk.
Knopp RH, Paramsothy P, Atkinson B, Dowdy A. Knopp RH, et al. Am J Cardiol. 2008 Apr 17;101(8A):48B-57B. doi: 10.1016/j.amjcard.2008.02.038. Am J Cardiol. 2008. PMID: 18375242 Review. - Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ, Watson KE, Talbert RL. Cziraky MJ, et al. J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. J Manag Care Pharm. 2008. PMID: 19891279 Review. - Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z. Reiner Z. Nutr Metab Cardiovasc Dis. 2013 Sep;23(9):799-807. doi: 10.1016/j.numecd.2013.05.002. Epub 2013 Aug 9. Nutr Metab Cardiovasc Dis. 2013. PMID: 23932901 Review. - Fasting plasma lipids, lipoproteins and apolipoproteins in Nigerian women using combined oral and progestin-only injectable contraceptives.
Oyelola OO. Oyelola OO. Contraception. 1993 May;47(5):445-54. doi: 10.1016/0010-7824(93)90096-p. Contraception. 1993. PMID: 8513671 Clinical Trial. - HDL-C: role as a risk modifier.
Barter P. Barter P. Atheroscler Suppl. 2011 Nov;12(3):267-70. doi: 10.1016/S1567-5688(11)70885-6. Atheroscler Suppl. 2011. PMID: 22152280 Review.
Cited by
- Research hotspots and future trends in lipid metabolism in chronic kidney disease: a bibliometric and visualization analysis from 2004 to 2023.
Wang Y, Liu T, Liu W, Zhao H, Li P. Wang Y, et al. Front Pharmacol. 2024 Sep 3;15:1401939. doi: 10.3389/fphar.2024.1401939. eCollection 2024. Front Pharmacol. 2024. PMID: 39290864 Free PMC article. - Explainable AI-prioritized plasma and fecal metabolites in inflammatory bowel disease and their dietary associations.
Onwuka S, Bravo-Merodio L, Gkoutos GV, Acharjee A. Onwuka S, et al. iScience. 2024 Jun 17;27(7):110298. doi: 10.1016/j.isci.2024.110298. eCollection 2024 Jul 19. iScience. 2024. PMID: 39040076 Free PMC article. - Causal association of smoking, blood lipids, and bladder cancer: Insights from a multivariable and mediation mendelian randomization investigation.
Wei H, Cheng X, Wang G, Li Z, Du W, Ju L, Shan D, Yu M, Fang Y, Qian K, Zhang Y, Xiao Y, Wang X. Wei H, et al. J Cancer. 2024 Feb 12;15(7):1929-1939. doi: 10.7150/jca.92306. eCollection 2024. J Cancer. 2024. PMID: 38434974 Free PMC article. - Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk.
Gobeil É, Bourgault J, Mitchell PL, Houessou U, Gagnon E, Girard A, Paulin A, Manikpurage HD, Côté V, Couture C, Marceau S, Bossé Y, Thériault S, Mathieu P, Vohl MC, Tchernof A, Arsenault BJ. Gobeil É, et al. Eur Heart J. 2024 Mar 1;45(9):707-721. doi: 10.1093/eurheartj/ehad845. Eur Heart J. 2024. PMID: 38243829 - [Atherogenic index and its association with acute coronary ischemic syndrome mortality].
Rodríguez-Martínez BS, Hernández-González MA, Borrayo-Sánchez G, Solorio-Meza SE, Medina-Torres ÓM, Gutiérrez-Galván MX, De La Roca-Chiapas JM, Cruz-Aceves I, Fernández-Hernández JP. Rodríguez-Martínez BS, et al. Rev Med Inst Mex Seguro Soc. 2023 Sep 18;61(Suppl 2):S226-S232. Rev Med Inst Mex Seguro Soc. 2023. PMID: 38016097 Free PMC article. Spanish.
References
- Nature. 2006 Dec 14;444(7121):881-7 - PubMed
- Obesity (Silver Spring). 2011 Jan;19(1):216-9 - PubMed
- Circulation. 2005 Nov 29;112(22):3375-83 - PubMed
- Clin Chem. 1991 Mar;37(3):377-86 - PubMed
- Circulation. 2002 Mar 12;105(10):1162-9 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources